In the Q4 2025 earnings call, Hims & Hers CEO Andrew Dudum addressed the increased scrutiny of compounded GLP-1 drugs and its impact on the company's bottom line[1][3]. The company announced 2.5 million subscribers at the end of 2025, an increase of 282,000 from 2024[1]. Annual revenue for 2025 reached $2.35 billion, up from $1.5 billion in 2024, while net income remained close to $128 million[1]. For 2026, the company anticipates revenues in the range of 2.7 to 2.9 billion dollars[1][3]. Dudum emphasized the resilience of the weight business even without compound GLP-1 drugs and drew attention to other weight loss drugs[1]. The fourth quarter of 2025 brought in revenue of $617.8 million and earnings of 8 cents per share[3]. The forecast for the first quarter of 2026 is for revenue of $600 million to $625 million, below analysts' expectations, due to changes in diet drug supply, Super Bowl advertising and new product investments[3].